SkinBioTherapeutics - Resignation of CEO

Skinbiotherapeutics

13/02/2026 07:00

RNS Number : 8564S

SkinBioTherapeutics PLC

13 February 2026

 

 

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

Resignation of CEO And Changes in Leadership Responsibilities

 

13 February 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that CEO, Stuart Ashman, has resigned, having been suspended by the Board pending an investigation into matters relating to his conduct. The Company is undertaking a full investigation, supported by its professional advisors.

Martin Hunt, Non-Executive Chairman, will assume the role and responsibilities of Executive Chairman temporarily; he will be supported by the rest of the Board and Leadership team to provide business leadership and continuity. The Company has instigated a search to find an interim CEO to appoint as soon as possible, and to find a new, permanent CEO for the longer term.

The Company will update the Market and shareholders in due course. Until then, there will be no further comment at this time.

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

-Ends-

For more information please contact:

SkinBioTherapeutics plcMartin Hunt, Executive Chairman
 Emily Bertram, CFO
ir@skinbiotix.com
Singer Capital Markets(Nominated Adviser & Broker)
 Philip Davies
 James Todd
 Patrick Weaver
+44 (0) 020 7496 3000
Vigo ConsultingMelanie Toyne-Sewell, Rozi Morris
+44 (0) 20 7390 0230SkinBio@vigoconsulting.com


Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products. 

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.SkinBioTherapeutics.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
BOAMZGMZZZFGVZZ